29 acres of the site has planning status as developed land.
Some 29 acres of the overall site has planning status as developed land (Major Developed Site) comprising a vacant GSK research and development facility of 439,000 ft² (40,600 m²) of existing space with a total footprint of 204,000 ft².
Henry Richards, Managing Director of Lands Improvement Holdings Plc said: “This is an excellent addition to the strategic land portfolio of Lands Improvement on the back of a successful sale of £20 million (€23.5 mln.) of mature and non core assets, during the course of this year. The acquisition sits perfectly with Lands Improvement’s business plan to invest in new land opportunities. Whilst there remain challenges with planning changes we believe with our ability to access capital and our expertise and experience we can create value in the long term.”
GlaxoSmithKline were advised by Jones Lang LaSalle. Lands Improvements were advised by Bidwells and SJ Berwin.